How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?
Crossref DOI link: https://doi.org/10.1038/leu.2016.75
Published Online: 2016-04-29
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Barosi, G
Gale, R P
Text and Data Mining valid from 2016-04-29
Version of Record valid from 2016-04-29
Article History
Received: 7 January 2016
Accepted: 18 January 2016
First Online: 29 April 2016
Competing interests
: GB participated in advisory boards of Novartis and Sanofi.